5 Proven Strategies to Boost Conversion Through Smarter Payment Infrastructure
'Too many businesses lose customers at the very last step – the payment page. Our job is to make sure every payment has the best possible chance of success'— Tetyana Solovei, Chief Product Officer at Tranzzo
LONDON, ENGLAND, UNITED KINGDOM, May 14, 2025 / EINPresswire.com / -- Global payment platform Tranzzo has revealed five actionable strategies to help businesses convert more payments into revenue, not just process them. These insights come from hands-on work with international clients and are fully integrated into the company's Payment Orchestration Platform.
'Too many businesses lose customers at the very last step – the payment page. Our job is to make sure every payment has the best possible chance of success,' said Tetyana Solovei, Chief Product Officer at Tranzzo. 'It's not just about processing payments – it's about removing friction, adding intelligence, and driving revenue.'
5 Strategies from Tranzzo to drive higher conversion
Fewer clicks = More payments
Every extra action in the checkout process increases the risk of drop-off. Tranzzo simplifies the path to payment by integrating all major methods – from Apple Pay and Google Pay to region-specific solutions – directly into the flow, with no disruption.
✅Result: 12–18% average increase in conversion thanks to user-friendly payment options.
Localisation that converts
Customers pay more willingly when the experience feels familiar. Tranzzo automatically adapts payment flows by language, currency, preferred local methods, and UX expectations, tailored to each market.
✅ Result: higher trust, lower friction, more completed checkouts.
Dynamic routing to the right provider
Not all payment providers perform equally across geographies, currencies, or customer segments. Tranzzo uses real-time performance data to route each transaction through the optimal provider.
✅ Result: better success rates without manual effort.
Smart anti-fraud, without false declines
False positives hurt twice: you lose the transaction and customer trust. Tranzzo's machine learning–based fraud prevention models minimize fraud while preserving legitimate payments.
✅ Outcome: up to 98% of legitimate transactions go through successfully.
Data that drives decisions
Raw numbers don't solve problems. Tranzzo's platform provides deep analytics by provider, method, geography, and reason for decline, so businesses can act fast and fine-tune their payment strategy.
✅ You see what works. And fix what doesn't — instantly.
Tranzzo – a platform that adapts to you
The Payment Orchestration Platform by Tranzzo is built to give businesses full control of their payment infrastructure, without the complexity. It's designed to optimize, adapt, and scale as your business grows.
About Tranzzo
Tranzzo is a global payment platform that helps online businesses scale with smart payment infrastructure. Operating across Europe, MENA, Latin America, and Southeast Asia, Tranzzo specializes in payment orchestration, local payment adaptation, and intelligent transaction routing.
Polina Toropova
Tranzzo
email us here
Visit us on social media:
TikTok
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio
Wall Street Journal
19 minutes ago
- Wall Street Journal
U.K. Government Likely to Lean on Tax Rises to Avoid Budget Rules Breach, NIESR Says
The U.K. government is set to break its fiscal rules unless it raises taxes or cuts spending when it unveils its new budget plans later this year, the U.K.'s National Institute of Economic and Social Research said Wednesday. In a quarterly report, the U.K.'s leading economic research body also said inflation is likely to remain stubbornly high this year, but expects the Bank of England to lower borrowing costs Thursday and once more before the end of the year.
Yahoo
an hour ago
- Yahoo
Average age of UK cars reaches record high of almost 10 years
The average age of cars on UK roads has reached a record high of nearly 10 years, sparking environmental fears. Motoring research charity the RAC Foundation, which conducted the research, said drivers are benefiting from the improved 'build-quality' of modern cars, but this is 'bad news for the environment' as it is slowing the switch to electric models. It found the average age of cars licensed in the UK at the end of last year was nine years and 10 months. This is up from seven years and five months at the end of 2015. Petrol cars have the oldest average age by fuel type at 10 years and four months, following by diesels at 10 years and one month. The average plug-in hybrid was three years and four months old while battery electric cars were typically just two years and six months old. A total of nearly 34 million cars were licensed at the end of last year. Of these, about two in five (40.7%) were at least 10 years old, compared with 32.7% at the end of 2015. Steve Gooding, director of the RAC Foundation, said: 'On the plus side, for motorists, the design and build-quality of modern cars means they are looking good and running reliably for far longer. 'The days of them rusting away before your eyes are well and truly behind us. 'Even a 20-year-old car with a full service history can be a good bet for someone seeking a bargain buy that still looks up to date. 'The bad news for the environment is that the overall ageing of the fleet means the replacement of fossil-fuelled cars by those with very low or zero emissions is not happening as quickly as policy-makers hoped. 'To hit the Climate Change Committee's 2030 emission reduction targets without a cut in the number of miles driven, we believe that by the end of the decade there will need to be a 10-fold increase in the 1.3 million or so battery electric cars on the road at the close of 2024. 'That is going to require a huge push.'
